Efficacy and safety of second-generation antidepressants in the treatment of major depressive disorder.
about
Initial severity and antidepressant benefits: a meta-analysis of data submitted to the Food and Drug AdministrationEffectiveness and cost-effectiveness of antidepressants in primary care: a multiple treatment comparison meta-analysis and cost-effectiveness modelParoxetine versus other anti-depressive agents for depressionDuloxetine versus other anti-depressive agents for depressionAgomelatine versus other antidepressive agents for major depressionMirtazapine versus other antidepressive agents for depressionAgomelatine versus other antidepressive agents for major depressionMilnacipran versus other antidepressive agents for depressionReboxetine versus other antidepressive agents for depressionEscitalopram versus other antidepressive agents for depressionInterventions to improve occupational health in depressed peopleInterventions to improve occupational health in depressed peopleCitalopram versus other anti-depressive agents for depressionMirtazapine versus other anti-depressive agents for depressionVenlafaxine versus other anti-depressive agents for depressionDuloxetine versus other anti-depressive agents for depressionFluvoxamine versus other anti-depressive agents for depressionEscitalopram versus other anti-depressive agents for depressionMilnacipran versus other anti-depressive agents for depressionParoxetine versus other anti-depressive agents for depressionGetting the balance right: Established and emerging therapies for major depressive disordersMeta-analysis of major depressive disorder relapse and recurrence with second-generation antidepressantsEfficacy and tolerability of second-generation antidepressants in social anxiety disorderVenlafaxine for major depressionSelective serotonin reuptake inhibitors and cardiovascular events: A systematic reviewVilazodone for the treatment of major depressive disorder: an evidence-based review of its place in therapyExtended release quetiapine fumarate monotherapy for major depressive disorder: results of a double-blind, randomized, placebo-controlled studyAgomelatine in the treatment of major depressive disorder: potential for clinical effectivenessGlutamate receptor ion channels: structure, regulation, and functionSalvianolic acid B ameliorates depressive-like behaviors in chronic mild stress-treated mice: involvement of the neuroinflammatory pathwayChanges in body weight and psychotropic drugs: a systematic synthesis of the literatureDuloxetine compared with fluoxetine and venlafaxine: use of meta-regression analysis for indirect comparisonsMetareview on short-term effectiveness and safety of antidepressants for depression: an evidence-based approach to inform clinical practice.Cost-efficient treatment for uninsured or underinsured patients with hypertension, depression, diabetes mellitus, insomnia, and gastroesophageal reflux.Comparative risk for harms of second-generation antidepressants : a systematic review and meta-analysis.Depression in adults: drug and physical treatments.Antidepressants: relationship to the time to psychiatric readmission and probability of being in hospital in depressive patientsRationale and design of the randomised clinical trial comparing early medication change (EMC) strategy with treatment as usual (TAU) in patients with major depressive disorder--the EMC trialOptimism, response to treatment of depression, and rehospitalization after coronary artery bypass graft surgery.Treatment patterns associated with Duloxetine and Venlafaxine use for Major Depressive Disorder.
P2860
Q21092366-6FDCBA88-9C53-4C38-A15B-D90A5852075DQ21134108-2BF77355-72A7-4FEE-B694-75F65BACA47DQ24197507-3FAF1F0D-D8B9-47BD-8EFC-010C60A662DDQ24198808-8AD0255C-0FA3-4BFB-BD4E-629A0607D7FBQ24201746-98D095F0-025E-4E2E-83D7-C10F293438B5Q24234046-1AAAE8A7-F2DF-4CC3-889F-B5354F769056Q24234339-281DBC8A-8C03-4832-9626-4C592CADBA15Q24240125-0A7CA49D-65F1-43EE-8500-C562DE67B0C6Q24240504-8AC83E68-2FA8-41D9-B81A-B8ECCEEFF48EQ24241065-24D421DD-D861-4F05-9C03-137AD9B30E7AQ24243142-BFA9BE99-CD04-4EEB-A605-56F66C1E2B31Q24244462-6E9C77F5-2B5A-4821-8DAF-A719794BAB39Q24245653-1703C0D0-C56C-4A03-8CF9-3BEF751C9506Q24245696-048A0474-E714-4773-8AB8-C804AE92D93BQ24245701-A25031B4-1577-485A-8622-02C295E1E8B8Q24245784-E98CF665-903E-459A-AE6D-CED3D8AA6CBBQ24245886-9F42DBAE-8B08-4A8C-9B0E-5A576E14F644Q24245921-59CC423B-3BBD-4A67-BBC4-96793DE86336Q24246033-7A7FC76C-D5EB-4CF1-B120-509CC234EEC7Q24246040-5AEF4C47-8492-4822-80D3-44763F344B66Q24610225-D6D85509-F2D0-48EF-9E91-F35D1803EAB6Q24624760-82D0025E-F94A-4342-8B6F-A07133D31164Q24656009-CAA65D0C-1E0E-486B-90B6-34328F1BAAA8Q24678849-96727BF3-1824-4E8E-A0CB-5C1193383577Q28076706-04FCBB92-4582-4D8F-91D6-BAA10A499482Q28083651-7CC10E61-36B6-43DE-A704-EF02938EE127Q28254377-F6F59676-7D26-4B28-B07A-E2F792F2312BQ28274600-76697CFD-D715-43E8-9A1E-F1F7598F8471Q28290774-64506691-6BBD-4B54-A0FB-E7E054C5CF83Q28595805-EFC29E45-3A19-4E1C-B248-36C653385950Q28728401-E0049473-C06E-4F6A-84AD-19C1FEFFA559Q33251729-9EA17D02-1D2C-46EA-B131-C500621ABD59Q33303429-028D3E76-C17E-40D2-83BE-8D067246E9BDQ33323489-ED6AEAB2-A4E9-4D67-8255-029D2A006005Q33365152-5A70138A-C46F-4311-9DAD-9C13911296FCQ33448181-FB0122AE-8333-4213-B301-0DF885558F6CQ33611658-1481272B-2850-4D89-A046-1657B8CC01FFQ33724051-BE84AAD2-6E40-456E-8980-9CB68C212C54Q33751075-2618AF5E-5B3B-4471-840F-3CD56686CD42Q33807834-CD178C9F-13C6-4881-B1B6-4BF5B8DF2E85
P2860
Efficacy and safety of second-generation antidepressants in the treatment of major depressive disorder.
description
2005 nî lūn-bûn
@nan
2005 թուականի Սեպտեմբերին հրատարակուած գիտական յօդուած
@hyw
2005 թվականի սեպտեմբերին հրատարակված գիտական հոդված
@hy
2005年の論文
@ja
2005年論文
@yue
2005年論文
@zh-hant
2005年論文
@zh-hk
2005年論文
@zh-mo
2005年論文
@zh-tw
2005年论文
@wuu
name
Efficacy and safety of second- ...... of major depressive disorder.
@ast
Efficacy and safety of second- ...... of major depressive disorder.
@en
Efficacy and safety of second- ...... of major depressive disorder.
@nl
type
label
Efficacy and safety of second- ...... of major depressive disorder.
@ast
Efficacy and safety of second- ...... of major depressive disorder.
@en
Efficacy and safety of second- ...... of major depressive disorder.
@nl
prefLabel
Efficacy and safety of second- ...... of major depressive disorder.
@ast
Efficacy and safety of second- ...... of major depressive disorder.
@en
Efficacy and safety of second- ...... of major depressive disorder.
@nl
P2093
P1476
Efficacy and safety of second- ...... of major depressive disorder.
@en
P2093
Bradley N Gaynes
Kathleen N Lohr
Richard A Hansen
Timothy S Carey
P304
P356
10.7326/0003-4819-143-6-200509200-00006
P407
P577
2005-09-01T00:00:00Z